Zai Lab Stock Has Fallen to Value Levels
Commercial stage global biotech company Zai Lab (NASDAQ: ZLAB) stock has cratered (-82%) from a 52-week high of $178.91. The biotech generates revenues from licensing established medications to market in China in addition to its own cancer treatment pipeline of medications. The model of licensing drugs to finance its own research has led to higher…